TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
-2.75%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.85B
AUM Growth
+$2.85B
(-8.4%)
Cap. Flow
-$72.4M
Cap. Flow
% of AUM
-2.54%
Top 10 Holdings %
Top 10 Hldgs %
35.96%
Holding
185
New
14
Increased
26
Reduced
25
Closed
10
Top Buys
| 1 |
AstraZeneca
AZN
|
$13.5M |
| 2 |
Stryker
SYK
|
$11.3M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
$9.35M |
| 4 |
SPDR S&P Biotech ETF
XBI
|
$8.6M |
| 5 |
Becton Dickinson
BDX
|
$8.15M |
Top Sells
| 1 |
Moderna
MRNA
|
$37.6M |
| 2 |
Thermo Fisher Scientific
TMO
|
$32.3M |
| 3 |
Merck
MRK
|
$17.4M |
| 4 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
$16.4M |
| 5 |
Danaher
DHR
|
$15.3M |
Sector Composition
| 1 | Healthcare | 95.64% |
| 2 | Real Estate | 3.21% |
| 3 | Industrials | 0.19% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
HCA Healthcare
HCA
$95.4B
| $31.2M | 1.09% |
124,303
+12,342
| +11% | +$3.09M |
|
|
SYNH
27
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $30.9M | 1.08% |
381,570
-21,517
| -5% | -$1.74M |
|
28
Biogen
BIIB
$20.8B
| $28.6M | 1% |
135,639
| – | – |
|
29
Humana
HUM
$37.5B
| $27.7M | 0.97% |
63,560
-6,100
| -9% | -$2.65M |
|
30
Zoetis
ZTS
$67.6B
| $26.6M | 0.94% |
141,167
+18,670
| +15% | +$3.52M |
|
31
Alnylam Pharmaceuticals
ALNY
$58.6B
| $25.9M | 0.91% |
158,606
-31,089
| -16% | -$5.08M |
|
32
Boston Scientific
BSX
$159B
| $25.2M | 0.89% |
569,398
+33,356
| +6% | +$1.48M |
|
33
Guardant Health
GH
$8.11B
| $23.3M | 0.82% |
351,484
| – | – |
|
34
IQVIA
IQV
$31.4B
| $22.7M | 0.8% |
98,154
| – | – |
|
35
Jazz Pharmaceuticals
JAZZ
$7.99B
| $21.9M | 0.77% |
140,473
+23,158
| +20% | +$3.6M |
|
36
Icon
ICLR
$14B
| $21.5M | 0.75% |
88,237
-10,634
| -11% | -$2.59M |
|
37
Edwards Lifesciences
EW
$47.7B
| $20.9M | 0.73% |
177,188
| – | – |
|
|
38
Becton Dickinson
BDX
$54.3B
| $19.7M | 0.69% |
73,930
+30,623
| +71% | +$8.15M |
|
39
Welltower
WELL
$112B
| $19.5M | 0.69% |
203,083
| – | – |
|
40
DexCom
DXCM
$30.9B
| $18.8M | 0.66% |
36,671
-5,260
| -13% | -$2.69M |
|
41
Zimmer Biomet
ZBH
$20.8B
| $18.2M | 0.64% |
142,044
| – | -$545K |
|
|
ITCI
42
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $17.8M | 0.63% |
290,936
+54,489
| +23% | +$3.33M |
|
43
Sarepta Therapeutics
SRPT
$1.98B
| $17.8M | 0.62% |
227,697
-88,200
| -28% | -$6.89M |
|
44
Charles River Laboratories
CRL
$7.99B
| $17.6M | 0.62% |
61,990
| – | – |
|
45
Intuitive Surgical
ISRG
$158B
| $17.4M | 0.61% |
57,606
| – | – |
|
46
ResMed
RMD
$39.4B
| $17.2M | 0.6% |
70,999
-3,600
| -5% | -$873K |
|
47
Novo Nordisk
NVO
$252B
| $17M | 0.6% |
153,523
+35,174
| +30% | +$3.91M |
|
48
BioNTech
BNTX
$24.1B
| $16.2M | 0.57% |
95,042
+4,800
| +5% | +$819K |
|
49
Health Care Select Sector SPDR Fund
XLV
$33.8B
| $15.5M | 0.54% |
113,230
| – | – |
|
50
Ventas
VTR
$30.7B
| $15.3M | 0.54% |
248,131
| – | – |
|